Should postprandial glucose be routinely measured and treated to a particular target? No !BUSE, John B.Diabetes care. 2003, Vol 26, Num 5, pp 1615-1618, issn 0149-5992, 4 p.Article

Metabolic side effects of antipsychotics: Focus on hyperglycemia and diabetesBUSE, John B.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 4, pp 37-41Conference Paper

Effects of therapy in type 1 and type ₂ diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)DUNGAN, Kathleen M; BUSE, John B; RATNER, Robert E et al.Diabetes/metabolism research and reviews (Print). 2009, Vol 25, Num 6, pp 558-565, issn 1520-7552, 8 p.Article

Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizonBUSE, John B; ROSENSTOCK, Julio.Endocrinology and metabolism clinics of North America. 2005, Vol 34, Num 1, issn 0889-8529, viii, 221-235 [16 p.]Article

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert ForumRAZ, Itamar; RIDDLE, Matthew C; LEROITH, Derek et al.Diabetes care. 2013, Vol 36, Num 6, pp 1779-1788, issn 0149-5992, 10 p.Article

Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes: The ACCORD Eye SubstudyAMBROSIUS, Walter T; DANIS, Ronald P; PETERSON, Kevin A et al.Archives of ophthalmology (1960). 2010, Vol 128, Num 3, pp 312-318, issn 0003-9950, 7 p.Article

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improve Glycemic Control in Patients With Type 2 Diabetes Using Oral AgentsBUSE, John B; SESTI, Giorgio; SCHMIDT, Wolfgang E et al.Diabetes care. 2010, Vol 33, Num 6, pp 1300-1303, issn 0149-5992, 4 p.Article

Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD TrialRIDDLE, MatthewC; AMBROSIUS, Walter T; SCHNALL, Adrian et al.Diabetes care. 2010, Vol 33, Num 5, pp 983-990, issn 0149-5992, 8 p.Article

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesKOLTERMAN, Orville G; BUSE, John B; BARON, Alain D et al.The Journal of clinical endocrinology and metabolism. 2003, Vol 88, Num 7, pp 3082-3089, issn 0021-972X, 8 p.Article

Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert ForumCEFALU, William T; BUSE, John B; DEL PRATO, Stefano et al.Diabetes care. 2014, Vol 37, Num 9, pp 2647-2659, issn 0149-5992, 13 p.Article

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyBUSE, John B; NAUCK, Michael; PORTER, Lisa et al.Lancet (British edition). 2013, Vol 381, Num 9861, pp 117-124, issn 0140-6736, 8 p.Article

Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phaseBERGENSTAL, Richard M; TAMBORLANE, William V; WOOD, Michael A et al.Diabetes care. 2011, Vol 34, Num 11, pp 2403-2405, issn 0149-5992, 3 p.Article

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargineBUSE, John B; WOLFFENBUTTEL, Bruce H. R; HERMAN, William H et al.Diabetes care. 2011, Vol 34, Num 2, pp 249-255, issn 0149-5992, 7 p.Article

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)ZINMAN, Bernard; GERICH, John; BUSE, John B et al.Diabetes care. 2009, Vol 32, Num 7, pp 1224-1230, issn 0149-5992, 7 p.Article

Primary prevention of cardiovascular diseases in people with diabetes mellitus : A scientific statement from the American heart association and the american diabetes associationBUSE, John B; GINSBERG, Henry N; PIGNONE, Michael P et al.Diabetes care. 2007, Vol 30, Num 1, pp 162-172, issn 0149-5992, 11 p.Article

A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United StatesBUSE, John B; CAVAZZONI, Patrizia; HORNBUCKLE, Kenneth et al.Journal of clinical epidemiology. 2003, Vol 56, Num 2, pp 164-170, issn 0895-4356, 7 p.Article

Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetesMERZ, C. Noel; BUSE, John B; TUNCER, Diane et al.Journal of the American College of Cardiology. 2002, Vol 40, Num 10, pp 1877-1881, issn 0735-1097, 5 p.Article

Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titrationBUSE, John B; HAN, Jenny; MILLER, Stephan et al.Current medical research and opinion. 2014, Vol 30, Num 7, pp 1209-1218, issn 0300-7995, 10 p.Article

Diabetes Screening With Hemoglobin A_1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School CohortBUSE, John B; KAUFMAN, Francine R; LINDER, Barbara et al.Diabetes care. 2013, Vol 36, Num 2, pp 429-435, issn 0149-5992, 7 p.Article

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 DiabetesROSENSTOCK, Julio; SHENOUDA, Sylvia K; BERGENSTAL, Richard M et al.Diabetes care. 2012, Vol 35, Num 5, pp 955-958, issn 0149-5992, 4 p.Article

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetesBUSE, John B; WOLFFENBUTTEL, Bruce H. R; HERMAN, William H et al.Diabetes care. 2009, Vol 32, Num 6, pp 1007-1013, issn 0149-5992, 7 p.Article

Design of the Future REvascularization Evaluation in patients with Diabetes mellitus : Optimal management of Multivessel disease (FREEDOM) TrialFARKOUH, Michael E; DANGAS, George; DOMANSKI, Michael et al.The American heart journal. 2008, Vol 155, Num 2, pp 215-223, issn 0002-8703, 9 p.Article

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes : a randomised, open-label, non-inferiority study. CommentarySCHEEN, Andre J; DRUCKER, Daniel J; BUSE, John B et al.Lancet (British edition). 2008, Vol 372, Num 9645, issn 0140-6736, 1197-1198, 1240-1250 [13 p.]Article

Quality of diabetes care in U.S. academic medical centers: Low rates of medical regimen changeGRANT, Richard W; BUSE, John B; MEIGS, James B et al.Diabetes care. 2005, Vol 28, Num 2, pp 337-342, issn 0149-5992, 6 p.Article

The Safety of Incretin-Based Therapies—Review of the Scientific EvidenceDRUCKER, Daniel J; SHERMAN, Steven I; BERGENSTAL, Richard M et al.The Journal of clinical endocrinology and metabolism. 2011, Vol 96, Num 7, pp 2027-2031, issn 0021-972X, 5 p.Article